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Abstract 
Rationale: Twist is a key transcription factor for induction of epithelial-mesenchymal transition 
(EMT), which promotes cell migration, invasion, and cancer metastasis, confers cancer cells with 
stem cell-like characteristics, and provides therapeutic resistance. However, the functional roles and 
targeted genes of Twist in EMT and cancer progression remain elusive.  
Methods: The potential targeted genes of Twist were identified from the global transcriptomes of 
T47D/Twist cells by microarray analysis. EMT phenotype was detected by western blotting and 
immunofluorescence of marker proteins. The dual-luciferase reporter and chromatin 
immunoprecipitation assays were employed to observe the direct transcriptional induction of 
ROR1 by Twist. A lung metastasis model was used to study the pro-metastatic role of Twist and 
ROR1 by injecting MDA-MB-231 cells into tail vein of nude mice. Bio-informatics analysis was 
utilized to measure the metastasis-free survival of breast cancer patients. 
Results: Twist protein was proved to directly activate the transcription of ROR1 gene, a receptor of 
Wnt5a in non-canonical WNT signaling pathway. Silencing of ROR1 inhibited EMT process, cell 
migration, invasion, and cancer metastasis of basal-like breast cancer (BLBC) cells. Knockdown of 
ROR1 also ameliorated the pro-metastatic effect of Twist. Furthermore, analyses of clinical 
specimens indicated that high expression of both ROR1 and Twist tightly correlates with poor 
metastasis-free survival of breast cancer patients.  
Conclusion: ROR1 is a targeted gene of Twist. Twist/ROR1 signaling is critical for invasion and 
metastasis of BLBC cells. 
Key words: ROR1, Twist, EMT, tumor metastasis, basal-like breast cancer (BLBC) 
Introduction 
Breast cancer is the most common malignancy in 
women worldwide; about 90% of breast cancer deaths 
are the result of metastasis [1]. Breast cancer is a 
heterogeneous disease in terms of tumor histology, 
clinical presentation, and response to therapy. There 
are four major subtypes based on gene expression 
profiling: luminal A, luminal B, ErbB2, and basal-like 
[1, 2]. BLBC cells are characterized by the lack of 
expression of estrogen receptor (ER), progesterone 
receptor (PR), and epidermal growth factor receptor 2 
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(HER2) and positive expression of basal markers 
(Cytokeratin 5/6 (CK5/6) and CK14) [3]. BLBC cells 
undergo epithelial-mesenchymal transition (EMT) 
and highly express several basal markers [4]. Several 
transcriptional factors have been reported to be 
involved in the regulation of EMT, and Twist and 
Snail are two major transcriptional factors that 
contribute to the induction of EMT process [5-8]. 
During mesoderm development in Drosophila, Snail 
functions as a transcriptional repressor to prevent 
expression of genes that belong to ectoderm, whereas 
Twist serves as a transcriptional activator to induce 
mesodermal gene expression [9, 10]. These results 
suggest that Snail and Twist work synergistically to 
induce EMT. A previous study has reported the 
mechanism underlying gene transcriptional activation 
by Twist [2]; however, the functional roles of Twist in 
EMT and cancer progression are still not fully 
characterized.  
Receptor tyrosine kinases (RTKs) are crucial to 
cell differentiation, proliferation, and migration. The 
aberrant expression of RTKs has been observed in 
different types of cancer cells [11-14]. Therefore, the 
identification and subsequent targeting of specific 
RTKs that overexpress uniquely in malignant cells, 
but not in normal cells, is crucial to anticancer 
therapies [15]. Receptor tyrosine kinase-like orphan 
receptors (RORs), as members of the RTKs family, 
have been recently brought into focus in the scientific 
community for the diagnosis and treatment of 
different cancer types [4, 13, 15, 16]. In humans, the 
expression of ROR1 is predominantly limited to 
embryo and fetus and it is not observed in adult 
tissues; however, the expression profile of ROR1 in 
cancer is quite different [15]. Similar to altered 
expression and activity of RTKs in different cancer 
types, the overexpression of ROR1 has been found in 
malignant cancers, such as chronic lymphocytic 
leukemia (CLL) [15], lung adenocarcinoma [13], and 
ovarian cancer [17]. High expression of ROR1 in 
tumor cells is associated with enhanced cell 
migration, EMT, increased risk of tumor relapse and 
metastasis, as well as poor prognosis [18-20]. 
Recently, ROR1 has been identified as a receptor for 
Wnt5a, which induces non-canonical Wnt signaling, 
potentially leading to enhanced tumor cell survival, 
cell movement, and polarity during development. 
Silencing of ROR1 in metastatic breast cancer cell lines 
attenuated expression of EMT markers, and impaired 
their migration/invasion capacity as well as 
metastatic potential [21-23]. Therefore, ROR1 may 
serve as a potential therapeutic target for patients 
with aggressive tumor [24]. However, its manner of 
transcriptional regulation and how tumor cells 
maintain high levels of ROR1 still remain elusive. 
In this study, we identified that Twist serves as a 
key factor for the transcriptional activation of ROR1 in 
BLBC cells by occupying the ROR1 gene promoter, 
and demonstrated that increased ROR1 expression is 
responsible for Twist-mediated EMT and breast 
cancer metastasis. 
Methods 
Microarray data analysis 
Microarray data of Twist expression in T-47D 
cells was deposited in the Gene expression Omnibus 
database with the accession number GSE53222. Raw 
data were normalized by Affymetrix Expression 
Console Software.  
Cell culture 
T47D, MDA-MB231, Hs578T, and 293T cells 
were obtained from ATCC. T47D cell line was 
cultured in RPMI-1640 (Life Technologies) with 10% 
FBS (Life Technologies) and 0.2 U/mL bovine insulin 
(Sigma). Hs578T was maintained in DMEM (Life 
Technologies) supplemented with 10% FBS (Life 
Technologies) and 0.01 mg/mL bovine insulin 
(Sigma). MDA-MB231 and 293T were cultured in 
DMEM (Life Technologies) with 10% FBS (Sigma). All 
cell lines were incubated in a humidified incubator at 
37 °C with 5% CO2. 
Plasmids construction 
The ROR1 promoter was purchased from 
Yingrun Biotechnology Inc. (Changsha, China). The 
sequences used for cloning ROR1 promoter mutants 
are shown in Supplementary Material. All plasmids 
above were verified by DNA sequencing. shRNA 
targeting ROR1 and Twist were purchased from 
Sigma. 
shROR1#4,5’-CCGGGCACCGTCTATATGGAG
TCTTCTCGAGAAGACTCCATATAGACGGTGCTT
TTT-3’; shROR1#5,5’-CCGGCTTTACTAGGAGACG 
CCAATACTCGAGTATTGGCGTCTCCTAGTAAAG
TTTTT-3’; shROR1#8,5’-CCGGCGGAGAGCAACTT 
CATGTAAACTCGAGTTTACATGAAGTTGCTCTC
CGTTTTT-3’; shTwist#1,5’-CCGGCCTGAGCAACAG 
CGAGGAAGACTCGAGTCTTCCTCGCTGTTGCTC
AGGTTTTT-3’; shTwist#2,5’-CCGGTCCGCAGTCTT 
ACGAGGAGCTCTCGAGAGCTCCTCGTAAGACT
GCGGATTTTT-3’. 
RNA extraction and qRT-PCR 
Total RNA isolation, qRT-PCR, and the 
quantification of target gene expression were 
performed as previously described [25]. Briefly, total 
RNA was isolated using TRIzol reagent (Invitrogen) 
according to the manufacturer's instructions. First- 
strand cDNA was synthesized using the Revert 
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AidTM First Strand cDNA Synthesis Kit (MBI 
Fermentas). The primers used to amplify the indicated 
genes are shown in Supplementary Material. 
Immunofluorescence 
Cells seeded in confocal dishes were fixed with 
4% paraformaldehyde and then kept stable in 0.2% 
Triton X-100 for 10 min to rupture the cell membranes. 
Following three PBS washings, non-specific antigen- 
binding sites were blocked by 2% BSA for 30 min. 
Cells were then incubated with anti-Twist (Merck 
Millipore, ABD29,1:200), anti-ROR1 (Santa cruz, 
sc-130867, 1;100) and anti-E-cadherin (BD, 610181, 
1:100) antibodies overnight at 4 °C. After washing, 
cells were incubated with secondary antibody 
(Invitrogen) for 60 min and the nuclei were stained 
with DAPI (Invitrogen) for 2 min, which was washed 
with PBS later. Cells were protected from light before 
observation with a fluorescence microscope. 
Western blotting 
Western blotting was performed as previously 
described [25]. Cells were collected and lysed by RIPA 
buffer (150 mM NaCl, 0.5% EDTA, 50 mM Tris, 0.5% 
NP40) and centrifuged for 20 min at 14,000 x g and 4 
°C. Fifty micrograms of harvested total protein was 
loaded and separated on the 8% SDS-polyacrylamide 
gradient gel. 
The proteins were then transferred onto 
polyvinylidene difluoride membranes and blocked 
with 5% non-fat milk for 2 h at room temperature. The 
membranes were incubated with primary antibody 
and horseradish peroxidase-conjugated secondary 
antibody, and proteins were then detected using an 
ECL chemiluminescence system (Pierce). Primary 
antibodies used were as follows: Twist (Abcam, 
ab50581, 1:1000), ROR1 (Santa cruz, sc-130867, 1:1000), 
E-Cadherin (CST, 3195, 1:1000), N-Cadherin (CST, 
13116, 1:1000), Vimentin (CST, 5741,1:1000), ZO-1 
(CST, 8193, 1:1000) and β-Actin (CST, 4970, 1:1000). 
Transwell migration and invasion assay 
Cells were seeded into Boyden chambers 
containing 24-well Transwell plates with a pore size of 
8 µm (BD Bioscience). The upper chamber was either 
left uncoated for the migration assay or precoated 
with 50 µL of 1:8 diluted Matrigel (BD Bioscience) for 
the invasion assay. For the migration assay, the 
Hs578T (4×104) and MDA-MB231 (5×104) cells were 
seeded into the upper chamber; for the invasion assay, 
8×104 Hs578T and 1×105 MDA-MB231 cells were 
seeded into the upper chamber. The upper chamber 
was filled with 200 µL serum-free specified medium 
whereas the lower chamber was filled with specified 
medium containing 10% FBS. Following incubation 
for 16 h or 24 h at 37 °C, cells that had invaded into the 
lower chamber were fixed with 4% paraformaldehyde 
and stained with crystal violet for 1 h at room 
temperature, and counted in five randomly-selected 
microscopic fields. All these experiments were 
performed in triplicate. 
Dual-luciferase reporter assay 
Cells were seeded in 12-well plates until growth 
to 80% confluence. Then, flag-Twist as well as its 
controls were co-transfected with ROR1, ROR1 
mutants’ promoter constructs and internal control 
pRK-TK into the indicated cells. After transaction for 
48 h, the luciferase activity was measured using a 
Dual-luciferase Assay kit (Promega). Reporter 
luciferase activity was normalized to Renilla 
luciferase activity. 
Chromatin immunoprecipitation assay 
The chromatin immunoprecipitation assay was 
performed as described by the ChIP kit (Millipore, 
17-10085 & 17-10086) [25]. Briefly, each cell line was 
seeded in a 15 cm plate and allowed to grow to 
70-80% confluence. To fix cells, complete cell fixative 
solution (10% of the volume of the growth medium) 
was added to the existing culture medium. The 
fixation reaction was stopped by adding stop solution 
(5% of the volume of the growth medium) to the 
existing culture medium. The cells were collected by 
centrifugation, and the nuclear pellet was resus-
pended in chromatin immunoprecipitation (ChIP) 
buffer. The cell lysate was subjected to sonication and 
then incubated with 5 mg of antibodies overnight, 
followed by incubation with the protein A/G agarose 
beads overnight at 4 ℃. Bound DNA-protein 
complexes were eluted, and cross-links were reversed 
after a series of washes. The purified DNA was 
resuspended in TE buffer for qRT-PCR. The primers 
for the indicated promoters are shown in 
Supplementary Material. 
Immunohistochemical staining 
Human tissue specimens (HBre-Duc140Sur-01) 
was purchased from Shanghai Outdo Biotech CO. The 
primary antibodies against Twist (Merck Millipore, 
ABD29) or ROR1 (Santa cruz, sc-130867) were diluted 
1:3000 or 1:800, respectively, and then incubated at 4 
°C overnight in a humidified container. Following 
washing three times with PBS, the section was treated 
with a non-biotin horseradish peroxidase detection 
system according to the manufacturer’s instructions 
(Dako). The tissue samples were examined by two 
pathologists who were blinded to the pathological 
information, and immunoreactivity. For Twist and 
ROR1, each tissue sample was scored according to its 
staining intensity (0, none; 1, weak; 2, moderate; 3, 
strong), and the percentage of stained cells (0, 0%; 1, 
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1-24%; 2, 25-49%; 3, 50-74%; 4, 75-100%). The score for 
each tissue was calculated by multiplying the staining 
intensity and the percentage of stained cells, yielding 
a value between 0 and 12. Then, the ROC curve 
analysis was used to determine the immunohisto-
chemical cut-off for high or low expression. Cancers 
with scores above the cut-off value were considered to 
have high expression of the indicated molecule and 
vice versa. 
Statistical analysis 
Data were analyzed using SPSS software version 
16.0 (SPSS Inc.). The significance of differences was 
assessed using two-tailed Student’s t-test or a χ2 test, 
as appropriate. The relationship between Twist 
expression, ROR1 expression, and the clinical 
pathologic parameters was examined using Pearson 
χ2 test. The correlations between Twist expression, 
ROR1 expression, and overall survival curves were 
assessed using Kaplan-Meier plots and compared 
with the log-rank test. Univariate and multivariate 
Cox regression analyses were used to evaluate 
survival data. Differences were considered significant 
when the p-values were < 0.05. 
Animal experiments 
All animal experiments were performed in 
accordance with protocols approved by the Research 
Animal Resource Center of Sun Yat-sen University. 
The animal ethics number of this project is 
L102012016050I. All animals were obtained from 
Beijing Vital River Laboratory Animal Technology 
Co., Ltd (Beijing, China). A lung metastasis model 
was used. Indicated cells were harvested and washed 
twice with PBS. Approximately 2×106 cells 
resuspended in 150 µL PBS were injected into the tail 
veins of five-week-old female athymic mice. All mice 
were sacrificed 10 weeks after the injection, and the 
lungs were harvested. The metastatic nodules in each 
lung were counted. 
Results 
Twist induces ROR1 expression during EMT 
To investigate the potential targets of Twist, the 
global transcriptomes were analyzed in T47D cells in 
which Twist was overexpressed exogenously, 
compared with those cells transfected with vector 
control (Figure 1A). Intriguingly, we found 
expression changes of nearly 2000 genes in 
T47D/Twist cells that were more than 2-fold higher 
than those of vector control cells. Among them, 54 
genes encoded transmembrane proteins. ROR1, which 
was initially identified as a member of the receptor 
tyrosine kinase family, was revealed to be one of the 
most altered molecules (Figure 1B). As shown in 
Figure 1C-D, overexpression of Twist in T47D cells 
promoted ROR1 expression at both mRNA and 
protein levels. In addition, immunofluorescence 
staining also indicated a positive correlation between 
Twist and ROR1 expression (Figure 1E and Figure 
S1A). Taken together, these data indicate that Twist 
can induce ROR1 expression by promoting its 
transcription during EMT in breast cancer cells. 
ROR1 is a direct targeted gene of Twist 
After screening a panel of breast cancer cells, 
only in basal-like subtypes we find high Twist 
and ROR1 expression (Figure S2A). To investigate 
whether ROR1 is directly regulated by Twist, 
luciferase assays were performed to measure the 
effect of Twist on the ROR1 promoter reporter, which 
was cloned into a pGL-3 basic vector. As shown in 
Figure 2A, Twist promotes ROR1 promoter luciferase 
activity in HEK293T, Hs578T, and MDA-MB231 cells. 
In addition, ChIP results showed that Twist binds to 
the region of ROR1 promoter from -802 to -402 
(fragment 3) and from -6 to 399 (fragment 5); the 
Vimentin and GAPDH promoter were used as 
positive and negative controls, respectively (Figure 
2B-C). We found that there was one E-box motif in 
fragment 3 (Figure S3A) and two E-box elongated 
motifs [26, 27] in fragment 5 (EL1 and EL2) (Figure 
2D). Intriguingly, the promoter activity of ROR1 
marginally affected by mutating E-box in fragment 3 
(Figure S3B); however, its activity was greatly 
reduced by mutating either one or both of the two 
elongated E-box motifs in fragment 5 (Figure 2E). 
Furthermore, the elevation of ROR1 promoter activity 
by Twist was dependent on these two elongated 
E-box motifs (EL1 and EL2); as such, the effect of 
Twist was abolished by mutating either one of them 
(Figure 2F). Consistently, knockdown of Twist, which 
led to the expression of ZO-1 and the suppression of 
Vimentin, also decreased the mRNA and protein level 
of ROR1 in Hs578T and MDA-MB231 cell lines 
(Figure 2G-J). These results demonstrate that Twist 
can promote ROR1 transcription by occupying its 
promoter in BLBC cells. 
ROR1 positively regulates cancer metastasis in 
BLBC 
A previous study proved that ROR1 plays an 
important role in cell proliferation and is associated 
with enhanced tumor cell growth [28] (Figure S4A-B). 
To further determine the roles of ROR1 in BLBC, five 
pairs of short hairpin RNAs (shRNA) were used to 
knockdown endogenous ROR1 expression. As shown 
in Figure S5A, the shROR1#4, shROR1#5 and 
shROR1#8 had the best knockdown efficiency in 
Hs578T cells. As has been reported, knockdown of 
 Theranostics 2018, Vol. 8, Issue 10 
 
 
http://www.thno.org 
2743 
ROR1 reduced Vimentin expression, and increased 
ZO-1 expression, in Hs578T and MDA-MB-231cells 
(Figure 3A-B), suggesting that suppression of ROR1 is 
sufficient to inhibit the EMT process in breast cancer 
cells [21]. Furthermore, silencing of ROR1 
significantly inhibited the migration and invasion of 
both Hs578T and MDA-MB231 cells (Figure 3C-F and 
Figure S5B-C). Moreover, knockdown of ROR1 also 
reduced the number of metastatic nodules when 
MDA-MB-231 cells were injected into the tail veins of 
mice (Figure 3G-H). Taken together, ROR1 positively 
regulates cell migration, invasion, and cancer 
metastasis in BLBC. 
 
 
Figure 1. Twist promotes the expression of ROR1. (A-B) Representative heatmaps from global comparative transcriptome analysis indicating genes that are up-regulated 
upon Twist overexpression. (C) The relative mRNA levels of the indicated genes were normalized to the GAPDH level in the T47D cells stably transfected with 
pLenti6.3/V5-vector or pLenti6.3/V5-Twist as determined by qRT-PCR. The results are expressed as the mean ± SD of three independent experiments. * P < 0.05 using Student’s 
t-test. (D) The indicated proteins were analyzed by Western blotting in T47D cells stably expressing pLenti6.3/V5-vector or pLenti6.3/V5-Twist, as indicated. (E) T47D cells 
stably expressing pLenti6.3/V5-vector or pLenti6.3/V5-Twist were analyzed by immunofluorescence as indicated. Scale bars, 50μm. 
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Figure 2. Twist directly upregulates ROR1 by occupying its promoter. (A) The indicated cells overexpressing empty vector or Twist were transfected with ROR1 
promoter linked to luciferase, and, after 48 h, luciferase activity was assayed. (B) Illustration of the ROR1 promoter region with the indicated Twist-binding capability. "+" 
indicates binding and "-" indicates no binding based on the results shown in (C). (C) MDA-MB-231 cells were analyzed by ChIP using anti-Twist antibody. (D) Schematic 
illustration of wild-type ROR1 promoter and its mutants. (E) ROR1 promoters (wild-type or mutant) linked to luciferase were transfected into 293T cells, and, after 48 h, 
luciferase activity was assayed. (F) The indicated cells overexpressing empty vector or Twist were transfected with ROR1 promoter (wild-type or mutant) linked to luciferase, 
and, after 48 h, luciferase activity was assayed. (G, I) The indicated cells stably transfected with control or Twist shRNA were used to analyze the mRNA level of the indicated 
molecules by qRT-PCR. (H, J) The indicated cells stably transfected with control or Twist shRNA were used to analyze the protein levels by Western blot. 
 
Table 1. Correlation between ROR1 expression and 
clinicopathologic characteristics of breast cancer patients 
  ROR1 expression Chi-square test 
Characteristics n Low or none 
No. cases (n) 
High  
No. cases(n)   
p value χ2 
Age    0.385 0.756 
≤50 63 41 22   
>50 71 41 30   
Clinical Stage    0.380 1.936 
TNM1 11 6 5   
TNM2                      77 51 26   
TNM3 46 25 21   
T classification    0.682 0.764 
T1 26 15 11   
T2 94 57 37   
T3 14 10 4   
N classification    0.083 6.667 
N0 51 30 21   
N1  40 30 10   
N2 34 19 15   
N3 9 3 6   
Tumor Size      
≤5 109 65 44 0.459 0.600 
>5 25 17 8   
Pathology grade        0.001* 13.653 
I 9 10 1   
II 117 71 43   
III 8 1 8   
Vital status (at 
follow-up) 
   0.017* 5.748 
Alive 91 62 29   
Death 43 20 23   
*P＜0.05. 
ROR1 mediates Twist-induced breast cancer 
metastasis 
It is known that Twist can induce the EMT 
process in breast cancer cells [1]. To investigate the 
relationship between Twist and ROR1 during EMT 
process, we tested the dependence of increased EMT 
and metastasis due to overexpression of Twist on 
ROR1. As expected, silencing of ROR1 abolished the 
EMT markers alteration induced by Twist in both 
Hs578T and MDA-MB231 cells (Figure 4A-B). 
Consistently, silencing ROR1 also inhibited the 
increased migration, invasion, and cancer metastasis 
mediated by Twist in both Hs578T and MDA-MB-231 
cells (Figure 4C-H and Figure S6A-B). These results 
demonstrate that Twist promotes EMT process and 
metastasis by inducing ROR1 expression. 
Twist and ROR1 expression are positively 
correlated in breast cancer tissues. 
The clinical significance of the regulation of 
ROR1 by Twist was then evaluated in 134 breast 
cancer patient tissues by immunohistochemical (IHC) 
staining. Using both anti-Twist and anti-ROR1 
antibodies, 23 of 134 tissues were shown to co-express 
high levels of Twist, whereas 60 of 134 tissues were 
shown to co-express high levels of ROR1. Moreover, 
the level of these two proteins was positively 
correlated (Figure 5A and Figure S7A). In addition, 
both Twist and ROR1 were associated with poor 
overall survival in breast cancer patients (Figure 
S7B-C). The chi-squared test revealed that the ROR1 
level is related to pathology grade (p=0.001) and vital 
status (p=0.017) (Table 1), and the univariate and 
multivariate analyses revealed that the ROR1 
expression level (p=0.021), with a HR of 2.024 and a 
95% CI of 1.106-3.706, is an independent prognostic 
factor in patients with breast cancer (Table 2). We also 
found that ROR1 mRNA expression is positively 
correlated with that of Twist1 in breast cancer patient 
samples from The Cancer Genome Atlas [TCGA] 
database after analyzing by ChIPBase v2.0 (Figure 5B) 
[29, 30]. We analyzed 220 patients with breast cancer 
in the GEO database. After separating patients into 4 
groups based upon their relative expression of Twist 
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and ROR1, we found that both high Twist (Figure 5C) 
and ROR1 (Figure 5D) expression predict shorter 
DMFS in these breast cancer tissue samples. These 
data suggest that the Twist/ROR1 signaling is a new 
biomarker to predict clinical outcomes in breast 
cancer patients.  
 
 
 
Figure 3. ROR1 positively regulates migration, invasion and cancer metastasis in BLBC. (A-B) The indicated molecules were analyzed by Western blot in the 
Hs578T and MDA-MB-231 cells with stable ROR1 knockdown. (C-F) Cell migration and invasion were determined in the indicated stable cell lines. These experiments were 
repeated at least three times. The results are expressed as the mean ± SD. * p < 0.05 and ** p < 0.01, *** p < 0.001 using Student’s t-test. (G) MDA-MB-231 cells stably 
transfected with control or shROR1 were injected into the lateral tail vein of nude mice. The left panel presents macroscopic appearances of metastatic lung tumors; central and 
right panels present the H&E staining. Scale bars, 40×,500μm; 200×,100μm. (H) Illustration of the statistical results (n=6). The results are expressed as the mean ± SD. ** P < 
0.01 using Student’s t test. 
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Figure 4. The promotion of cell migration, invasion and cancer metastasis after Twist overexpression primarily depends on ROR1. (A-B) The indicated 
molecules were analyzed by Western blot in the Hs578T and MDA-MB-231 cells stably expressing control, ROR1 shRNA, Twist, or both, as indicated. (C-F) Cell migration and 
invasion were determined in the indicated stable cell lines. The results are expressed as the mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01 and *** P < 0.001 
using Student’s t-test. (G-H) An in vivo lung metastasis model was established in nude mice using MDA-MB-231 cells stably expressing control, ROR1 shRNA, Twist, or both, as 
indicated. (G) Representative results of gross and H&E staining (middle scale: 40×; right scale: 200×) of metastatic lung nodules. Scale bars, 40×,500μm; 200×,100μm. (H) 
Illustration of the statistical results (n = 6). The results are expressed as the mean ± SD. * P < 0.05, *** P < 0.001 using Student’s t-test. 
 
Table 2. Univariate and multivariate analysis for overall survival 
(Cox proportional hazards regression model) 
Variable  Univariate analysis Mutivariate analysis 
No. p value HR 95% CI p value 
ROR1 expression  0.021* 2.024 1.106-3.706 0.022* 
low expression 63     
high expression 71     
Age  0.309 1.683 0.871-3.250 0.121 
≤50 63     
>50 71     
T classification  0.204 1.305 0.360-4.728 0.685 
T1+ T2 120     
T3 14     
N classification  0.088 1.571 0.787-3.136 0.204 
N0 51     
N1+ N2+ N3 
 
83     
Tumor size  0.168 1.691 0.578-4.944 0.338 
≤5 109     
>5 25     
 
 
 
 
 
 
 
Discussion 
Accumulating evidences indicate that Twist is a 
key transcriptional regulator that endows cells with 
malignant traits, such as invasion, migration and 
therapeutic resistance. However, identification of new 
Twist-targeted genes and how these genes function 
during these events are required to fully understand 
the molecular mechanism of EMT and metastasis. In 
this report, we have demonstrated that Twist 
functions as a transcriptional activator for ROR1 gene 
expression in EMT and breast cancer, and 
Twist-induced EMT and breast cancer metastasis 
partially depends on ROR1.  
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Figure 5. The expression of Twist and ROR1 correlates with clinical prognosis in breast cancer. (A) Representative immunohistochemical staining of Twist and 
ROR1 from 134 paraffin-embedded breast cancer tissues. Scale bars, 100μm. (B) Correlation of the expression of ROR1 and Twist in TCGA breast cancer datasets. (C-D) 
Graphs were derived from published data available through the PubMed GEO database (GSE16446 and GSE19615). Kaplan–Meier curves depict the prognostic impact of Twist 
(C) and ROR1 (D) expression on distant metastasis-free survival (DMFS), respectively. Statistical differences were determined by log-rank test. 
 
In previous studies, several RTKs were observed 
to be significantly deregulated in cancers including 
vascular endothelial growth factor (VEGF) [31], 
epidermal growth factor receptor (EGFR) [32], 
fibroblast growth factor receptor (FGFR) [33], and 
RTK-like orphan receptor 1 (ROR1) [34]. These 
deregulated RTKs offer promising drug targets for 
cancer treatment with specific targeting by 
monoclonal antibodies. Recently, ROR1 has been 
identified as the receptor of Wnt5a [18, 22, 35], which 
activates non-canonical WNT signaling to promote 
breast cancer metastasis [21]. Almost a third of human 
breast cancer cases express high levels of ROR1, 
which is associated with activation of AKT, cAMP 
response element-binding protein (CREB), and 
enhanced tumor cell growth [28, 36]. Moreover, the 
expression of ROR1 is particular to BLBC cell lines 
that have high metastatic potential [21]. Intriguingly, 
we showed previously that Twist can recruit BRD4 to 
direct WNT5A gene expression in BLBC by binding to 
WNT5A gene promoter and enhancer; therefore, Twist 
may contribute to activation of non-canonical WNT 
signaling [2]. Herein, we established a T47D 
derivative cell line stably expressing Twist, and this 
cell line displayed a mesenchymal cell phenotype. In 
this process, Twist activates ROR1 gene transcription 
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in a luminal breast cancer cell line, which contains 
little expression of endogenous ROR1. In the other 
hand, silencing ROR1 in BLBC cell lines, Hs578T and 
MDA-MB231, inhibited Twist-induced EMT, cell 
migration, invasion, and cancer metastasis. 
Furthermore, a positive correlation between Twist 
and ROR1 was observed in breast cancer patient 
tissues; this may become a new marker to predict 
DMFS and overall survival of patients with breast 
cancer. Mechanistically, we discovered that although 
the -802 to -402 (fragment 3) region of ROR1 promoter 
has Twist-binding affinity, mutation of the E-box in 
this region did not affect ROR1 promoter reporter 
activity. However, mutations on either one or both of 
two elongated E-box motifs in the -6 to 399 (fragment 
5) region could abrogate the Twist-induced ROR1 
promoter reporter activity. Previous studies identified 
a non-canonical E-box motif, which is called E-box 
elongated CANNNTG, that may also serve as a 
potential DNA-binding site [26, 27]. Although there is 
no report on whether Twist can recognize this E-box 
elongated motif, our evidences showed that 
mutations in this motif can abrogated Twist-induced 
ROR1-promoter activity, suggesting that Twist may 
recognize this E-box elongated motif on the gene 
promoter. 
In summary, our findings suggest that not only 
Wnt5a but also ROR1 is a transcription target of 
Twist. We revealed cross-talk between Twist- 
mediated EMT and non-canonical WNT signaling in 
metastatic breast cancer, because both Wnt5a and 
ROR1 are involved in this pathway. Therefore, Twist 
functions as an important transcriptional factor to 
activate non-canonical WNT signaling, and thus 
promote EMT, cell migration, invasion, and cancer 
metastasis in BLBC. Moreover, ROR1 may serve as a 
better therapeutic target for metastatic breast cancer 
compared with Wnt5a, because either Wnt5a or 
ROR1-induced non-canonical WNT signaling can be 
blocked by ROR1 inhibitor. The involvement of Twist 
and ROR1 in a pathway regulating EMT, as shown 
here, may inform the design of new drugs or 
treatments for patients with BLBC. 
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